Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study

Autoimmunity Reviews

Volumn 14, Issue 2, 2015, Pages 168-173

  Moulis, Guillaume ^a,b,c   Lapeyre Mestre, Maryse ^a,b,c   Montastruc, Jean Louis ^a,b,c   Sailler, Laurent ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSERM   (France)

Author keywords

Immune thrombocytopenia; Pharmacoepidemiology; Rituximab; Splenectomy; Thrombopoietin receptor agonist

Indexed keywords

AZATHIOPRINE; DANAZOL; DAPSONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; THROMBOPOIETIN RECEPTOR;

ADULT; AGE; AGED; ARTICLE; AUTOIMMUNE DISEASE; BRAIN HEMORRHAGE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; DISEASE DURATION; DRUG EXPOSURE; FEMALE; FRANCE; GASTROINTESTINAL HEMORRHAGE; GENDER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE THROMBOCYTOPENIA; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; NON CORTICOSTEROID TREATMENT; POPULATION RESEARCH; SPLENECTOMY; THERAPY; THROMBOCYTOPENIA; AGONISTS; CHRONIC DISEASE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ADULT; AGED; CHRONIC DISEASE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN;

EID: 84922597581     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.10.017     Document Type: Article

References (23)

1. Lo E., Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev 2014, 13:577-583.
2. Deane S., Teuber S.S., Gershwin M.E. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 2010, 9:A342-A349.
3. Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
4. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
5. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88:3-40.
6. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009, 113:2386-2393.
7. Moulis G., Sailler L., Adoue D., Lapeyre-Mestre M. Pharmacoepidemiology of immune thrombocytopenia: protocols of FAITH and CARMEN studies. Therapie 2014, 69:437-448.
8. Tuppin P., de Roquefeuil L., Weill A., Ricordeau P., Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010, 58:286-290.
9. Moulis G., Palmaro A., Montastruc J.-L., Godeau B., Lapeyre-Mestre M., Sailler L. Epidemiology of incident immune thrombocytopenia in France: a nationwide population-based study. Blood 2014, [pii: blood-2014-05-578336. [Epub ahead of print] PMID:25305203].
10. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
11. Bannay A., Chaignot C., Blotière P.-O., Weill A., Ricordeau P., Alla F., et al. Score de Charlson à partir des données du Sniiram chaînées au PMSI: faisabilité et valeur pronostique sur la mortalité à un an. Rev Epidemiol Sante Publique 2013, S9.
12. Khellaf M., Michel M., Schaeffer A., Bierling P., Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005, 90:829-832.
13. Moulis G., Sailler L., Sommet A., Lapeyre-Mestre M., Derumeaux H., Adoue D. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity. Am J Hematol 2013, 89:41-46.
14. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
15. Khellaf M., Fain O., Terriou L., Viallard J.-F., Cheze S., Roudot-Thoraval F., et al. Safety and efficacy of rituximab in adult's immune thrombocytopenia (ITP): results after one-year of follow-up in 252 patients from the Prospective French ITP-Ritux Registry. Blood 2013, 122:450.
16. Maloisel F., Andrès E., Zimmer J., Noel E., Zamfir A., Koumarianou A., et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 2004, 116:590-594.
17. Godeau B., Durand J.M., Roudot-Thoraval F., Tennezé A., Oksenhendler E., Kaplanski G., et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol 1997, 97:336-339.
18. Haute Autorité de Santé Purpura thrombopénique immunologique de l'enfant et de l'adulte. Protocole national de diagnostic et de soins 2009 Available at, [Accessed 01 July 2014]. http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-12/ald_2_pnds_pti_imune_enft_adulte_web.pdf.
19. Arnal C., Piette J., Léone J., Taillan B., Hachulla E., Roudot-Thoraval F., et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002, 29:75-83.
20. Khellaf M., Chabrol A., Mahevas M., Roudot-Thoraval F., Limal N., Languille L., et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol 2014, 89:194-198.
21. Quantin C., Benzenine E., Hägi M., Auverlot B., Abrahamowicz M., Cottenet J., et al. Estimation of national colorectal-cancer incidence using claims databases. J Cancer Epidemiol 2012, 2012:298369.
22. Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
23. Levy R., Mahévas M., Galicier L., Boutboul D., Moroch J., Loustau V., et al. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev 2014, 13:1055-1063.